Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with a FMDV O Mya98 lineage virus in pigs 4 and 7 days post vaccination  by Wilna, Vosloo et al.
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Early  protection  with  a high  potency  (>6PD50) foot-and-mouth  disease  (FMD)  O1 Manisa  (Middle-East
South Asia  lineage)  vaccine  against  challenge  with  O/VIT/2010  (O  Mya98  lineage)  was  tested  in  pigs.  Only
two  pigs  that  were  vaccinated  seven  days  prior  to challenge  had  any  demonstrable  antibodies  as  a  result
of vaccination  at the time  of  challenge.  However,  80%  and  60%  of  pigs  that  were  vaccinated  seven  and
four  days  prior  to  coronary  band  challenge  were  protected.  Vaccination  signiﬁcantly  reduced  the  amount
of virus  excreted  in  nasal  swabs,  saliva  and  faeces  compared  to unvaccinated  and  infected  controls.  Virus
and  viral RNA  could  be  detected  in some  pigs  until  termination  of  the experiment  14  days  after  challenge.
Antibodies  to  the  non-structural  proteins  (NSP)  were  detected  in  only  one  pig  that  was  challenged  four
days  post  vaccination  (dpv)  and  transiently  in  two  pigs  that  were  challenged  seven  dpv  at only  one time
point.  For  each  vaccine  and  control  group,  a group  of unvaccinated  pigs  were  kept  in the  same  room  but
with  no  direct  contact  with  the infected  pigs  to determine  whether  vaccination  prevented  transmission.
Despite  the  presence  of live  virus  and viral  RNA  in  these  indirect  contact  pigs,  the  groups  in contact  with
the  vaccinated  and  infected  pigs  did  not  develop  clinical  signs  nor  did  they  sero-convert.  Contact  pigs  in
the  same  room  as unvaccinated  challenged  controls  did  show  signs  of  disease  and  virus  infection  that
resulted  in sero-conversion  to  the  NSP.  A  breach  of the  wall  that separated  the two  groups  at  nine  days
post  challenge  might  have  contributed  to this  ﬁnding.  This  study  showed  that  high potency  vaccine  can
provide  protection  to  pigs  soon  after  vaccination  and that  aerosol  transmission  within  rooms  is  a  rare
event.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Foot-and-mouth disease (FMD) is a highly contagious viral dis-
ase that affects species belonging to the Artiodactylae. The disease
s characterised by an acute, systemic vesicular disease with lesions
eveloping on areas of friction. Despite low mortality rates in adult
∗ Corresponding author. Tel.: +61 3 52275015; fax: +61 3 5227 5555.
E-mail address: wilna.vosloo@csiro.au (V. Wilna).
ttp://dx.doi.org/10.1016/j.vaccine.2015.04.045
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
animals, FMD  severely decreases livestock production and results
in devastating trade restrictions.
The causative agent, FMD  virus (FMDV), belongs to the Aph-
thovirus genus of the Picornaviridae family. Seven serotypes of
FMDV (A, O, C, Asia-1, SAT 1, SAT 2 and SAT 3) have been identi-
ﬁed on the basis of the ability of viruses to induce cross-protection
in animals. This cross-protection is serotype-restricted, and it is
not always complete when vaccines contain different subtypes and
variants of the same serotype [1].
Highly potent vaccines for emergency use have previously been
shown to protect cattle against airborne challenge as early as two
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2] and four [3] days post immunisation and pigs within four days of
accination [4,5]. Immunisation of pigs and cattle prior to challenge
an dramatically reduce the titre and duration of FMDV excre-
ion [4,6,7]. In these studies the challenge was with a homologous
irus. Protection against heterologous challenge has been shown
or serotypes A in cattle [8] but similar studies with serotype O did
ot yield satisfactory results [9,10].
FMD  is endemic in many parts of the world and occurs in most
ountries in South East Asia (SEA) where regular outbreaks of FMDV
erotypes O, A, and Asia-1 are reported [11–13]. FMDV serotype O
iruses belonging to serotype O/SEA topotype (Mya-98 and Cam-
4 strains), O/ME-SA topotype (PanAsia lineage and the derivative
an-Asia-2 sub-lineage) and O/Cathay topotype, serotype A (ASIA
opotype; SEA-97 strain) and serotype Asia-1 have been identiﬁed
14–16].
Pigs are seen as the biggest risk of disease dissemination dur-
ng an outbreak [7]. While it is possible to control the movement
f people, animals and their products, it is not possible to control
erosols that have been implicated in previous outbreaks [17–19].
t is therefore important to decrease virus loads and quantify the
ffect of vaccination on levels of virus excreted during a heterolo-
ous challenge. In this paper we report the early protection afforded
y the O1 Manisa high potency vaccine in pigs challenged with a
irus isolated in Vietnam in 2010.
. Materials and methods
.1. Cell lines, viruses and vaccine
Baby hamster kidney (BHK)-21 cells were used for any virus
elated work. The challenge virus (O/VIT/2010) belongs to the
MDV O Mya98 lineage [20] and was isolated in 2010 from pig feet
issue and was passaged ﬁve times to a titre of 107.05 TCID50/ml.
A high potency (>6PD50) monovalent O1 Manisa double oil adju-
ant vaccine was prepared by M/s. Merial Company Limited, United
ingdom for this study.
.2. Preparation of pig challenge virus
The work was performed according to the Australian Animal
thics Code (AEC1465 and 1497) in the animal facility of NAVETCO,
ietnam. Three month old sero-negative cross-bred Landrace pigs
ere obtained from a commercial piggery in Vietnam.
Tissue culture adapted virus at 106.5 TCID50/ml  was  inoculated
ither into the foot-pad [21,22] of the left-fore limb at multiple
ites (2 ml;  0.1 ml/site in each digit) or intravenously (1 ml)  into
he ear vein and intramuscularly (1 ml)  on the mid  neck region
n two pigs. Epithelium was collected from lesions other than the
noculation sites and a 10% suspension prepared by homogenizing
issue in PBS (pH 7.4). Two additional pigs were inoculated with
 ml  of the suspension into the foot-pad of left-fore limb at multiple
ites and the process repeated in two more pigs. A 10% suspension
as prepared from vesicular lesions, titrated and stored at −80 ◦C.
.3. Pig immunisation, challenge and sample collection
Three groups of 10 pigs each were divided into sub-groups con-
isting of ﬁve pigs (Fig. 1). Groups O-V7 (n = 5) and O-V4 (n = 5)
ere vaccinated intramuscularly in the neck with 2 ml  vaccine (21G
eedle) and challenged seven and four days post vaccination (dpv)
espectively. Group O-UV (n = 5) was not vaccinated but constituted
nvaccinated challenged controls. Groups O-UVC7, O-UVC4 and O-
VC (n = 5 each) were used as unvaccinated indirect contacts and
oused in the same room as O-V7, O-V4 and O-UV respectively
ut with a physical partition consisting of a waist-high steel wall
etween the groups (Fig. 1). Animals shared the same air handling (2015) 2778–2785 2779
facility but were not in direct physical contact and were provided
with separate feed and water troughs.
Animals in O-V7, O-V4 and O-UV were challenged with 105.0
TCID50 pig derived virus by inoculation in two sites in the left-hind
foot pad (0.2 ml/site). Rectal temperatures were recorded daily and
animals were observed for 14 days for clinical disease. Nasal sec-
retions, saliva and faeces were sampled daily using cotton swabs
for virus isolation (0.5 ml  of Eagle’s Basal Medium with 10% FCS and
ﬁeld antibiotics) and viral genome detection (0.5 ml  of lysis buffer
with carrier RNA; Stratec Biomedical, Germany). Swabs were sub-
mersed in buffer immediately after collection and stored at −80 ◦C.
Clotted blood for serum was collected on −7, −4, 0, 5, 7, 10 and 14
days post-challenge (dpc) and blood in EDTA buffer on 0–7, 9, 10
and 14 dpc.
Observations and sample collection were performed in O-UVC7,
O-UVC4 and O-UVC groups as described above. Clotted blood for
serum was collected on days 0, 5, 7, 10 and 14 dpc and unclotted
blood on 0, 3, 5, 7, 9, 10 and 14 dpc.
2.4. Virus isolation and antigen ELISA
Virus isolation from the salivary and nasal swabs was performed
in 96-well plates by adding 100 l of log10 dilutions to each well in
duplicate and observing for cytopathic effect (CPE) at 24 and 48 h
post-infection using standard procedures. Positive samples were
conﬁrmed by ELISA [23].
2.5. Real-time quantitative RT-PCR for detection of viral RNA
Total RNA from the salivary, nasal and faecal swab samples
and blood collected in EDTA was extracted using the InviMag
Virus RNA Mini kit/KF96 (Stratec Molecular, Germany) on an auto-
mated nucleic acid extraction system (KingFisher* Flex Magnetic
Particle Processor, ThermoFisher Scientiﬁc, USA) following the
manufacturer’s protocol. The RNA was used for quantitative reverse
transcription PCR (RT-qPCR) using the Ambion AgPath-ID Master-
Mix  (Life Technologies, USA) as per standard protocols [24].
In vitro transcribed RNA was prepared to determine a standard
curve for each RT-qPCR run using Megascript T7 kit (Ambion, USA)
from a plasmid pBluescript KS+, cloned using a 550 base region
from the 5′UTR region of the FMDV genome [25].
2.6. Serology for virus antibodies to the structural and
non-structural proteins (NSP) of FMDV
The solid phase competition ELISA (SPCE) was performed to
detect antibodies to the structural proteins on sera samples at 1:5
dilutions in duplicate following standard procedures [26] using rab-
bit (O1 Manisa) and guinea pig (O1 BFS) antisera and O1 Manisa
inactivated antigen. Final OD values were expressed as the percent-
age inhibition relative to the mean OD of the OD max  control wells
i.e. 100 − (100 × (OD test serum mean/OD OD  Max  control mean)).
Samples that showed <50% inhibition of the OD max  control were
scored negative and those ≥50% were considered positive.
A competitive ELISA (c-ELISA) developed at AAHL to detect anti-
bodies to the NSP was  performed in duplicate on the sera samples at
1:5 dilutions as described [27] using baculovirus expressed recom-
binant 3ABC protein and chicken antibodies raised against the
protein. The ﬁnal OD values were expressed as for the SPCE and
cut-off values were the same.
2.7. Statistical analysisQuantitative data were assessed for normality using commer-
cially available software (MINITAB Statistical Software, Release
13.32, Minitab Inc, State College, Pennsylvania, USA). Quantitative
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Fig. 1. Experimental lay-out of challenge and indirect contact groups to study
ata were transformed using the natural logarithm prior to statis-
ical analysis and descriptively presented as the median and range.
ategorical variables were compared between groups using chi-
quare or Fisher exact tests. Quantitative variables were compared
mong experimental groups at each day using Kruskal–Wallis tests
ollowed by multiple pairwise Mann–Whitney U tests with Bon-
erroni correction of P values. Correlation between quantitative
ariables was estimated using Spearman’s rho. Linear mixed mod-
ls were used to estimate the effect of treatment group on viral
itres and rectal temperatures. All models included a random effect
erm for pig and ﬁxed effect terms for treatment group, experi-
ental day, and barrier status (intact versus breakage). A combined
odel of multiple specimens also included a ﬁxed effect for sample
ype. Bonferroni correction was used to adjust P values for multi-
le post-hoc comparisons. Statistical analyses were performed in
ommercially available software (IBM SPSS Statistics Version 22,
nternational Business Machines Corp., Armonk, New York, USA)
nd results were interpreted at the 5% level of signiﬁcance.
. Results
.1. Preparation of pig challenge virus
Initial inoculation of the cell culture adapted virus via the foot-
ads did not result in clinical disease. Intravenous infection of two
ther pigs resulted in lesions in one pig three days post infection
dpi). At the third passage, both animals had disseminated disease
–3 dpi and material collected from these pigs was used in the
accine study. common  air  handling  unit]
ﬁcacy of high potency O1 Manisa vaccine against O/VIT/2010 (Mya-98 strain).
3.2. Vaccine efﬁcacy study
All animals in O-UV showed generalised disease, deﬁned as
lesions at locations other than the inoculation site, within 48–72 h
post-challenge (Table 1). One pig (no. 5) died 2 dpc and necropsy
showed infarction in the epicardium. The other four animals (nos.
1–4) showed lesions on all sites between 2 and 4 dpc. On 9 dpc the
pigs breached the steel wall and a small hole was  created where
pigs from O-UV and O-UVC could have direct contact. None of the
contact animals in O-UVC showed disease until 13 dpc, when one
pig (no. 9) showed lesions on the feet and tongue and was removed.
At 14 dpc, when the trial was  terminated, necropsy examination of
pig no. 10 showed heart lesions but no other lesions were noticed
in this or the three remaining pigs (Table 1).
In O-V7, one pig (no. 21) showed secondary lesions on all three
feet other than the site of inoculation at 2 dpc. One animal (no. 22)
showed lines of infarction on the heart musculature upon necropsy
at 14 dpc, while O-UVC7 remained clinically normal.
One pig (no. 12) in O-V4 had secondary lesions on the non-
inoculated feet and lower lip at 3–4 dpc. Pig no. 15 developed a
lesion on the tongue at 4 dpc that resolved quickly. None of the
contact animals in O-UVC4 showed any clinical signs (Table 1). The
cumulative incidence of clinical signs over the 14 day study period
is presented in Supplementary Table 1.3.3. Pyrexia and viraemia in pigs as determine by RT-qPCR
Pyrexia was intermittent in most cases (Table 1). Three of the
pigs in O-UV had detectable RNA in the blood between 3 and 7 dpc;
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Table  1
Summary of the clinical outcome and presence of genomic material and live virus after challenge with O/VIT/05/2010.
Days post challenge 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Groups ID
O-UV 1 NGV SV  NG SGV  NGV SGV NGV SGV NG SGV NGV SG NG NG NG SG NG SG NG 
2   NG SG  NGV SGV NG SGV NGV SGV NG SGV NGV SG NGV NG SG NG SG NG SG NG SG NG
3  SV NGV SGV  NG SGV NG SG NG SG NGV SGV NV SG NG SG NG SG NG SG 
4  SV NGV SGV NGV SGV NG SGV  NGV SG NGV SGV NGV SG NG SG NG SG NG SG SG NG SV NG SG
5  H
O-UVC 6 SV SGV SG NV SV SV SV SGV NG SG
7  SV SV NV SGV SG SGV SV SG SG 
8  SV NV SGV SV SGV SG 
9  NV SV SG SG SG  SGV
10  SV SV SG NV H SG 
O-V4 11  NV NGV SV NGV SG NGV SG NG SG NG NG SG NG SGV NG NGV SG NG SG NG NG
12   NG SG  NGV SGV NG SG NG NG SG NG SG NG SGV NG NG 
13  SV NGV SG NG SG NG SG NG SG NG SG NG SG NG NG SG NG NG 
14  NG SG NG SG NG SG NG NG SG NGV SG NG NG SG NG NG SG NG
15   NG SG NG SG M SG NG SG NG SG NG SG SG NG NV NG SG
O-UVC4 16  NV SV NV SV NGV SV NG SV NV NG SV NV SV NV SV NG NV SGV
17  SV SV NGV NGV SV NG SG SG NG
18  SV NG NV NG NG SV NV SG NV NG SG 
19  NV NV SG NG SV NV NG NV NV SV SG NG SG NG
20  NGV NG SV SV NGV NG NG NV 
O-V7 21  NGV SGV  NG SG NG SGV NGV SG NGV SG NG SV NG NV SV SV SV NG SV NV
22  NGV SGV NGV SGV NG SG NG NV NG SGV NG NG SV H
23  NG SG NG SG NG SG NG NGV NG SGV NGV NGV SG SV NG NG SG SV
24    NG SG NG SGV NG SV SGV NG SV SV NG SG SG NG SV NG
25  NG SG NG SG NG NG NG NGV NG NG SV SV SV NG 
O-UVC7 26  NV SV 
27  
28  SV 
29  SV NV SV 
30  
 ngue
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1 Lesion at site of inoculation;  Lesion at any other site including feet, mouth, to
ied/Euthanised; shaded boxes—temperature ≥40 ◦C; NG SG—Viral RNA detected in
wabs  respectively by virus isolation on cell culture; NGV SGV—both RNA and live vi
ig no. 2 was positive at 3 dpc, pig no. 3 at 7 dpc, with only pig
o. 4 showing RNA on two consecutive days (4–5 dpc). One pig
n O-V4 tested positive at 7 dpc. The levels of RNA were variable
8.7 × 103–2.7 × 106 copy numbers). Surprisingly, one pig in O-UVC
ad 7.9 × 105 copy numbers in the blood at 14 dpc (results not
hown).
.4. Detection of FMDV by RT-qPCR and virus isolation from nasal
nd saliva swab samples
Samples were deemed positive when either RNA was detected
r virus isolated. Saliva swabs from all surviving pigs in O-UV were
ositive from 1 to 10 dpc, while pig no. 4 tested positive for viral
NA until 14 dpc (Table 1). Nasal swabs were positive between 1
nd 7 dpc, while pigs nos. 2 and 4 tested positive until 14 dpc. Pigs
n O-UVC tested positive for virus in the saliva swabs from 2 dpc.
efore the breach at 9 dpc, three of the ﬁve pigs had live virus
solated from the saliva at one or more time points.
All pigs in O-V7 tested positive in both oral and nasal swabs at
 dpc. From 3 dpc, the recovery from swabs was  intermittent but
resent in at least three pigs daily until 14 dpc. Live virus was  iso-
ated from the nasal swab of one pig until 9 dpc. Viral RNA was
etected in the nasal and saliva swabs of three of the contact pigs
O-UVC7) between 1 and 3 dpc but not subsequently.
Virus was detected in either the nasal or saliva swabs of pigs nos.
1 and 13 in O-V4 at 1 dpc. At 2 dpc, all samples were positive. From
 dpc the detection was  intermittent, but RNA was still detected in
wabs at 14 dpc. Contact pigs (O-UVC4) were also positive from
 dpc, with live virus found in nasal and saliva swabs of three pigs and snout, indicating disseminated disease; H—lesion in heart muscle;  Animal
 and saliva swabs respectively by RT-PCR; NV SV—virus detected in nasal and saliva
tected in the nasal and saliva swabs, respectively.
on that day. Live virus was  also recovered from the saliva of one pig
at 14 dpc (Table 1).
3.5. Antibody responses in the different groups of pigs
Only two pigs that were vaccinated seven days prior to challenge
(O-V7: nos. 23 and 24) were sero-positive to the structural proteins
on the day of challenge (Table 2). At 5 dpc, all ﬁve pigs in O-V7 and
O-V4 had sero-converted including one pig (no. 2) in O-UV that had
not been vaccinated, but challenged. By 10 dpc, all the challenged
pigs were sero-positive. In the contact groups, sero-conversion was
detected in a single pig (no. 7) in O-UVC between 10 and 14 dpc.
None of the pigs had detectable antibodies to FMDV NSP until
10 dpc when all pigs in O-UV were positive and remained so until
14 dpc. One of the contact pigs (no. 7) in O-UVC had antibodies to
the NSP at 14 dpc. One pig (no. 12) in O-V4 was  sero-positive on
both 10 and 14 dpc, while two pigs in O-V7 (nos. 24 and 25) were
sero-positive only on 10 dpc (Table 2).
3.6. Comparison of the viral RNA recovered from samples across
the different groups
The amount of viral RNA detected from the saliva swabs was
statistically different among all treatment groups when evalu-
ated for all sampling times (Table 3; P < 0.001). Furthermore, both
vaccinated groups had signiﬁcantly less RNA compared to the
unvaccinated challenged O-UV; however there was no signiﬁcant
difference between O-V4 and O-V7. Pigs in O-UV had signiﬁ-
cantly more detectable RNA than O-V7 at 4, 6, 9, 10, and 14 dpi.
There were no signiﬁcant differences observed between O-UV
2782 V. Wilna et al. / Vaccine 33 (2015) 2778–2785
Table  2
Results of cELISA for antibodies against structural proteins against FMDV and NSP antibody ELISA.
Group Pig ID cELISA NSP antibody ELISA
0 dpc 5 dpc 7 dpc 10 dpc 14 dpc 0 dpc 5 dpc 7 dpc 10 dpc 14 dpc
O-UV 1 Neg Neg Pos Pos Neg Neg Pos Pos
2  Neg Pos Pos Pos Neg Neg Pos Pos
3  Neg Neg Pos Pos Neg Neg Pos Pos
4  Neg Neg Pos Pos Neg Neg Pos Pos
5  Neg – – – – Neg – – – –
O-UVC 6  Neg Neg Neg Neg Neg Neg Neg Neg
7  Neg Neg Pos Pos Neg Neg Neg Pos
8  Neg Neg Neg Neg Neg Neg Neg Neg
9  Neg Neg Neg Neg Neg Neg Neg –
10  Neg Neg Neg Neg Neg Neg
O-V4 11  Neg Pos Pos Pos Neg Neg Neg Neg
12  Neg Pos Pos Pos Neg Neg Pos Pos
13  Neg Pos Pos Pos Neg Neg Neg Neg
14  Neg Pos Pos Pos Neg Neg Neg Neg
15  Neg Pos Pos Pos Neg Neg Neg Neg
O-UVC4 16  Neg Neg Neg Neg Neg Neg Neg Neg
17  Neg Neg Neg Neg Neg Neg Neg Neg
18  Neg Neg Neg Neg Neg Neg Neg Neg
19  Neg Neg Neg Neg Neg Neg Neg Neg
20  Neg Neg Neg Neg Neg Neg Neg Neg
O-V7 21  Neg Pos Pos Pos Neg Neg Neg Neg
22  Neg Pos Pos Pos Neg Neg Neg Neg
23  Pos Pos Pos Pos Neg Neg Neg Neg
24  Pos Pos Pos Pos Neg Neg Pos Neg
25  Neg Pos Pos Pos Neg Neg Pos Neg
O-UVC7 26  Neg Neg Neg Neg Neg Neg Neg Neg
27  Neg Neg Neg Neg Neg Neg Neg Neg
28  Neg Neg Neg Neg Neg Neg Neg Neg
29  Neg Neg Neg Neg Neg Neg Neg Neg
30  Neg Neg Neg Neg Neg Neg Neg Neg
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Pos: positive; Neg: negative; – animal removed.
nd O-V4 or between O-V4 and O-V7 at any individual sampling
ay.
In nasal swabs, the amount of viral RNA detected was statisti-
ally different among all treatment groups when evaluated over
ll days (Table 4; P < 0.001). Furthermore, O-V7 group had signiﬁ-
antly less detectable RNA compared to both O-UV and O-V4. The
mount of detectable RNA was not different between O-UV and
-V4. The amount of detectable RNA was different between chal-
enged and contact groups for multiple experimental days but there
ere no detectable differences among O-UV, O-V4 and O-V7 at any
ndividual experimental day.
Levels of RNA detected in faecal swabs were statistically differ-
nt between all treatment groups when evaluated over all sampling
imes (Supplementary Table 2; P < 0.001). Furthermore, O-UV had
igniﬁcantly more detectable RNA compared to O-V4 but not O-
7.
When adjusting for the observed barrier breakage in a multivari-
ble model, the amount of RNA detected was different among the
reatment groups (Table 5; P < 0.001). Pigs within both vaccinated
roups had less detectable RNA than O-UV. O-V7 had less detectable
NA compared to O-V4 but the overlapping conﬁdence intervals
uggested that the difference was not statistically different. The
mount of FMDV RNA detected varied by specimen type with the
owest levels in blood and the highest in nasal swabs. Overlapping
onﬁdence intervals for nasal and oral swabs suggested that the
ifference between these two specimen types was not statistically
igniﬁcant.
The amount of FMDV RNA detected in the blood was posi-
ively correlated with the presence of clinical lesions (rho = 0.211,
 < 0.001).4. Discussion
Most vaccine efﬁcacy studies are performed with homologous
challenge and there is a dearth of information on protection when
there are genetic and antigenic differences between the vaccine
strain and challenge virus. Antigenic matching results between the
challenge virus and the O1 Manisa vaccine are not available, how-
ever, comparisons between another virus that was isolated during
2010 in Vietnam indicated an acceptable match (Annual reports of
the World Reference Laboratory 2010, 2011). In this study, there
was 80% and 60% protection in pigs vaccinated seven and four days
prior to a heterologous challenge, respectively, indicating that vac-
cination can provide some protection at early time points. Similar
results were obtained when pigs were challenged by exposure to
aerosols generated by infected pigs [4], a method that is seen as less
traumatic and a more natural route of exposure compared to the
coronary band route used in our study. However, pigs vaccinated
four and seven days prior to exposure could infect cohorts with
which they had direct contact [4,28,29] indicating that vaccination
does not fully prevent disease transmission within a pen soon after
vaccination whereas those vaccinated 14 days prior to infection did
not infect their cohorts [28].
More importantly, vaccination lowered the amount of virus
excreted compared to the unvaccinated challenged controls,
although there was not a statistically signiﬁcant difference between
the two  vaccine groups. This is in agreement with other vaccine
experiments [28–32] although in at least one experiment the pigs
vaccinated seven days before challenge excreted more virus than
the infected controls on some occasions [28]. Therefore although
vaccinated pigs may  still become infected, the overall viral load
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Table  3
Median (range) viral RNA copy numbers recovered from saliva swabs via PCR. All contact animals were unvaccinated.
Day PC Unvaccinated Exposed 4 days post vaccination Exposed 7 days post vaccination P value*
Challenged
(O-UV)
Contact
(O-UVC)
Challenged
(O-V4)
Contact
(O-UV4)
Challenged
(O-V7)
Contact
(O-UV7)
1 NGDa,b (NGD,
1.3E + 2)
NGDb NGDb NGDb 2.8E + 4a (NGD,
9.2E + 4)
NGDb 0.002
2  6.7E + 5a
(6.1E + 3,
2.5E + 6)
NGDb 1.8E + 4a,b
(NGD, 1.2E + 5)
NGDb 1.0E + 5a
(6.0E + 3,
1.0E + 7)
NGDb <0.001
3  6.7E + 5a
(2.9E + 5,
2.3E + 6)
NGDb 4.0E + 5a,b
(7.4E + 4,
1.8E + 6)
NGDb 1.2E + 4a (NGD,
2.4E + 7)
NGDb 0.001
4  7.9E + 5a
(4.0E + 5,
1.2E + 6)
NGDb (NGD,
1.0E + 3)
5.2E + 3a,b
(5.3E + 2,
7.5E + 4)
NGDb (NGD,
4.3E + 4)
NGDb (NGD,
2.2E + 5)
NGDb 0.001
5  7.5E + 5a
(1.5E + 5,
5.8E + 6)
NGDa,b (NGD,
8.9E + 3)
8.6E + 2a,b
(NGD, 5.7E + 3)
NGDb NGDa,b (NGD,
3.5E + 4)
NGDb 0.004
6  7.8E + 4a
(3.2E + 4,
2.4E + 5)
NGDa,b (NGD,
1.0E + 7)
5.1E + 2a,b
(NGD, 2.1E + 4)
NGDb NGDb NGDb 0.003
7  9.4E + 4 (NGD,
7.2E + 6)
NGD (NGD,
2.5E + 6)
1.2E + 3 (NGD,
1.9E + 4)
NGD NGD (NGD,
4.7E + 3)
NGD 0.131
8  3.4E + 3a (NGD,
2.4E + 4)
NGDa (NGD,
4.0E + 5)
1.4E + 3a
(4.2E + 2,
4.4E + 3)
NGDa NGDa (NGD,
2.8E + 3)
NGDa 0.018
9  1.3E + 3a
(1.6E + 2,
1.2E + 4)
NGDb NGDb NGDb NGDb (NGD,
3.5E + 3)
NGDb 0.001
10  1.1E + 4a
(1.2E + 3,
1.4E + 4)
NGDb 3.7E + 2a,b
(NGD, 9.5E + 3)
NGDa,b (NGD,
2.0E + 3)
NGDb NGDb 0.002
11  NGD (NGD,
1.9E + 2)
NGD (NGD,
5.3E + 2)
NGD (NGD,
7.6E + 2)
1.7E + 3 (NGD,
2.9E + 3)
NGD (NGD,
1.7E + 3)
NGD 0.237
12  NGD (NGD,
2.2E + 2)
1.3E + 3 (NGD,
1.5E + 5)
NGD (NGD,
1.9E + 3)
NGD NGD NGD 0.087
13  ND 4.4E + 4
(4.4E + 4,
4.4E + 4)
NGD (NGD,
3.5E + 2)
NGD (NGD,
2.6E + 3)
NGD (NGD,
5.2E + 3)
NGD 0.148
14  NGDa (NGD,
2.0E + 2)
1.6E + 4a,b
(2.4E + 3,
2.5E + 4)
NGDa,b (NGD,
6.2E + 4)
NGDa,b (NGD,
2.6E + 3)
NGDb NGDb 0.010
Overall 1.3E + 3a (NGD,
7.2E + 6)
NGDb,d (NGD,
1.0E + 7)
NGDc (NGD,
1.8E + 6)
NGDb (NGD,
4.3E + 4)
NGDc,d (NGD,
2.4E + 7)
NGDb <0.001†
PC = post-challenge. NGD = no genome detected. ND = no testing done.
* Based on Kruskal–Wallis tests for a difference among the 6 treatment groups. Medians without superscripts in common are signiﬁcantly different based on pairwise
Mann–Whitney U tests after Bonferroni correction of P values.
† s in co
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sBased on mixed-effects linear regression over all days. Medians without superscript
f  P values.
nd infectious period may  be signiﬁcantly reduced in a facility
28,32,33] thereby assisting in disease control.
Live virus and/or viral RNA could be detected in the excretions
ntermittently until the study was terminated at 14 dpc, similar to
ther short term experiments where detection lasted until 11 dpc
28–30]. In one long term study, RNA was detected up to 28 dpc in
he saliva and probang of a vaccinated pig [31]. The implications of
hese ﬁndings are not clear, as in most instances no live virus could
e isolated.
The study furthermore aimed to determine if transmission
ould occur to unvaccinated pigs when kept in close, but indirect
ontact with vaccinated and infected pigs. The pigs kept next to
he unvaccinated challenged controls only showed disease at 13
nd 14 dpc. This followed a break in the wall that allowed pigs to
ave direct contact from 9 dpc. However, live virus and viral RNA
ere detected in these pigs from 2 dpc indicating that despite the
bsence of clinical signs and lack of sero-conversion, these pigs
ere exposed to live virus. Van Roermund [32] showed that walls
etween groups of pigs reduced transmission 10- to 20-fold com-
ared to within pen transmission. In addition, when pigs were
eparated by a wooden wall, transmission was  delayed to threemmon are signiﬁcantly different based on model results after Bonferroni correction
days after exposure, compared to within pen transmission that usu-
ally occurred within one day. Airborne transmission seems to be
relatively rare when pigs don’t have direct contact [34] and it is
speculated that faeces and urine may  also cause transmission [32].
In our experiment it was similarly possible that these excretions
may  have run between the pens, and this was certainly observed
with groups O-UV and O-UVC. The delayed infection could there-
fore be due to the lower amount of RNA found in faeces compared
to nasal and saliva samples.
Temperature was positively correlated with the presence of clin-
ical lesions (rho = 0.141, P = 0.003) but not viraemia (rho = 0.081,
P = 0.193). Three pigs had elevated temperatures on 0 dpc, possibly
due to stress. Viral RNA was detected only in the blood of needle
infected pigs on very few occasions between 3 and 7 dpc and not
in any of the pigs in group O-V7. The contact pig in O-UVC that had
RNA in the blood at 14 dpc, also showed evidence of heart lesions
and viral RNA in the saliva on that day. All pigs in O-UV had anti-
bodies to the NSP from 10 to 14 dpc indicating that sufﬁcient virus
replication had occurred to stimulate antibodies.
The detection of antibodies to the NSP is an important tool
during post-outbreak surveillance. Two pigs in O-V7 (nos. 24 and
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Table  4
Median (range) viral RNA copy numbers recovered from nasal swabs via PCR. All contact animals were unvaccinated.
Day PC Unvaccinated Exposed 4 days post vaccination Exposed 7 days post vaccination P value*
Challenged
(O-UV)
Contact
(O-UVC)
Challenged
(O-V4)
Contact
(O-UV4)
Challenged
(O-V7)
Contact
(O-UV7)
1 NGDa,b (NGD,
1.2E + 4)
NGDa NGDa NGDa (NGD,
1.3E + 3)
2.7E + 5b
(1.1E + 4,
4.9E + 6)
NGDa 0.001
2  1.8E + 5a
(4.2E + 4,
2.1E + 5)
NGDb 1.7E + 3a,b
(3.4E + 2,
8.6E + 4)
NGDb 5.5E + 5a
(2.8E + 4,
6.9E + 5)
NGDb <0.001
3  1.4E + 5a
(3.4E + 3,
6.1E + 5)
NGDb 4.9E + 4a
(1.1E + 3,
6.9E + 5)
NGDa,b (NGD,
1.4E + 3)
3.9E + 3a,b
(2.1E + 3,
1.5E + 5)
NGDb <0.001
4  1.2E + 5a
(7.4E + 3,
3.8E + 5)
NGDb 1.1E + 4a,b
(NGD, 1.0E + 5)
NGDa,b (NGD,
3.5E + 3)
2.4E + 3a,b
(NGD, 1.1E + 4)
NGDb 0.001
5  2.8E + 5a
(5.4E + 4,
3.1E + 5)
NGDb 1.2E + 3a,b
(6.4E + 2,
2.0E + 5)
4.8E + 3a,b
(NGD, 5.6E + 4)
1.2E + 4a,b
(NGD, 4.1E + 4)
NGDb 0.002
6  5.8E + 5a
(1.7E + 5,
7.8E + 5)
NGDb 5.1E + 2a,b
(3.1E + 2,
1.5E + 4)
NGDb (NGD,
5.2E + 3)
1.2E + 3a,b
(NGD, 4.6E + 4)
NGDb 0.001
7  1.3E + 3 (NGD,
1.4E + 5)
NGD 2.6E + 3 (NGD,
1.0E + 5)
3.7E + 3 (NGD,
1.2E + 4)
NGD (NGD,
3.7E + 4)
NGD 0.071
8  2.9E + 3a
(7.2E + 2,
4.4E + 5)
NGDa 7.4E + 2a
(2.9E + 2,
3.1E + 4)
2.8E + 3a (NGD,
1.1E + 4)
4.2E + 3a (NGD,
3.8E + 5)
NGDa 0.005
9  8.5E + 3a
(5.6E + 3,
2.9E + 4)
NGDb NGDa,b (NGD,
2.5E + 2)
NGDb 9.2E + 2a,b
(NGD, 4.8E + 3)
NGDb 0.001
10  4.4E + 3a
(1.9E + 3,
1.2E + 4)
NGDb 2.8E + 3a,b
(NGD, 1.5E + 7)
NGDa,b (NGD,
2.1E + 3)
NGDa,b (NGD,
4.3E + 3)
NGDb 0.003
11  7.8E + 1 (NGD,
1.4E + 3)
NGD 2.4E + 2 (NGD,
4.1E + 3)
NGD NGD (NGD,
1.5E + 4)
NGD 0.084
12  NGD (NGD,
3.8E + 2)
NGD NGD (NGD,
4.5E + 2)
NGD (NGD,
2.4E + 4)
NGD (NGD,
1.2E + 4)
NGD 0.611
13  ND NGD 8.7E + 2 (NGD,
6.8E + 3)
NGD (NGD,
5.8E + 3)
6.0E + 3 (NGD,
5.0E + 4)
NGD 0.054
14  1.0E + 2 (NGD,
3.4E + 2)
NGD 2.5E + 2 (NGD,
2.8E + 3)
NGD (NGD,
2.2E + 3)
NGD (NGD,
1.6E + 3)
NGD 0.380
Overall 4.1E + 3a (NGD,
7.8E + 5)
NGDb 5.2E + 2a,c
(NGD, 1.5E + 7)
NGDd (NGD,
5.6E + 4)
2.1E + 3c (NGD,
4.9E + 6)
NGDb <0.001†
PI = post-challenge. NGD = no genome detected. ND = no testing done.
* Based on Kruskal–Wallis tests for a difference among the 6 treatment groups. Medians without superscripts in common are signiﬁcantly different based on pairwise
M
†
o
T
M
C
w
sann–Whitney U tests after Bonferroni correction of P values.
Based on mixed-effects linear regression over all days. Medians without superscripts in co
f  P values.
able 5
ultivariable model results including viraemia.
Variable Estim
Experimental group 
Contact with unvaccinated (O-UVC) −6.95
Contact with vaccinated pigs challenge 4 dpv (O-UVC4) −5.38
Contact with vaccinated pigs challenged 7 dpv (O-UVC7) −7.13
Vaccinated 4 days prior to challenge (O-V4) −1.99
Vaccinated 7 days prior to challenge (O-V7) −2.79
Unvaccinated challenged (O-UV) Refere
Barrier
Breakage 3.30 (
Intact  Refere
Sample type
Nasal swab 5.22 (
Oral  swab 4.38 (
Whole blood Refere
I = conﬁdence interval. Model estimates for the variables associated with days post-ino
as  removed from the ﬁnal model. All treatment groups were signiﬁcantly different (P <
wab  values were signiﬁcantly different (P = 0.018).mmon are signiﬁcantly different based on model results after Bonferroni correction
ate (95%CI) t Statistic P value
<0.001
 (−8.06, −5.85) −12.353 <0.001
 (−6.31, −4.44) −11.309 <0.001
 (−8.06, −6.20) −14.996 <0.001
 (−2.90, −1.09) −4.321 <0.001
 (−3.69, −1.88) −6.049 <0.001
nt
1.82, 4.77) 4.392 <0.001
nt
<0.001
4.50, 5.95) 14.092 <0.001
3.66, 5.11) 11.825 <0.001
nt
culation are not presented in the table. Pig sex was  not signiﬁcant (P = 0.198) so it
 0.05) except for the comparisons of O-UVC and O-UVC4 (P = 0.07). Nasal and oral
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5) were sero-positive for NSP antibodies on only 10 dpc but not
n 14 dpc, probably indicating a low level of virus replication,
onﬁrming ﬁndings from other studies that showed vaccination
esulted in a lower and shorter duration of responses to NSP [29].
oth these pigs had lesions only at the site of inoculation. One pig
n O-V4 that had generalised disease, sero-converted on 10 dpc and
emained positive until 14 dpc whilst one other pig in that group
hat had lesions on the inoculated foot away from the inoculation
ite, remained negative. None of the indirect contact pigs in O-UVC4
nd O-UVC7 sero-converted to NSP antibodies. However, viral RNA
nd on occasion live virus, could be detected in saliva and nasal
wabs of most of these pigs. It is therefore possible that the NSP
ests may  fail to identify all infected pigs during an outbreak.
Although vaccination did not protect all the challenged pigs, it
ecreased the amount of virus excreted and remains an important
ool for control during an outbreak.
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